Related Experiment Video
Updated: Feb 2, 2026

Author Spotlight: Improved Imaging for Neovascular Development in Congenital Heart Disease Research
Published on: April 26, 2024
Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia
Constantine E Kosmas1, Delia Silverio2, Julio Ovalle2
1Division of Cardiology, Department of Medicine, Mount Sinai Hospital, New York, NY, USA, cekosmas1@gmail.com.
Abstract:
Evolocumab is a PCSK9 inhibitor which is administered subcutaneously, and when added to statin therapy it has been shown to cause a significant incremental LDL-C reduction, leading to a reduction of cardiovascular risk. Evolocumab has a favorable side effect profile, and its self-administration at home appears to be safe and effective with the appropriate training and instructions from a health care provider. Current studies are showing encouraging results regarding adherence to evolocumab in real-life settings, and adherence rates to evolocumab appear to be better than those to statins. However, further larger studies are needed for a more definitive assessment of the short- and long-term patient adherence rates to evolocumab. In addition, reductions in the price of evolocumab may also be necessary to improve cost-effectiveness of the drug.
Related Concept Videos
Psychodynamic Perspectives on Personality
Psychodynamic theorists argue that unconscious...
Social Cognitive Perspective on Personality
Criticisms of the Evolutionary Perspective
Evolutionary psychology provides one explanation for these findings, suggesting...
The Behavioral Perspective on Personality
Resistivity
Resistance

